Incyte Corporation (NASDAQ:INCY) announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, …
Incyte Corporation (NASDAQ:INCY) announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 …
Array Biopharma Inc Leerink’s top analyst Michael Schmidt was out today with a favorable report on shares of Array Biopharma Inc (NASDAQ:ARRY), raising the …
Incyte Corporation (NASDAQ:INCY) announced that the U.S.
Incyte Corporation (NASDAQ:INCY) announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte’s investigational, highly …
Analysts were able to meet with management from Gilead Sciences, Inc. (NASDAQ:GILD) and Incyte Corporation (NASDAQ:INCY) to gain insight into both companies’ future plans.
Incyte Corporation (NASDAQ:INCY) announced new 28-week data from the Phase 3 RESPONSE-2 study of Jakafi® (ruxolitinib). The data show that Jakafi was superior to …
Incyte Corporation (NASDAQ:INCY) announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi® (ruxolitinib) in patients with …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Incyte Corporation (NASDAQ:INCY) announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations.
Incyte Corporation (NASDAQ: INCY) reported 2016 first-quarter financial results, including strong revenue growth driven by increased Jakafi® (ruxolitinib) sales in the U.S.
